Non-interventional Study With Nab-Paclitaxel (Abraxane®)
Launched by IOMEDICO AG · Sep 17, 2012
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
The main focus of this non-interventional study is set on answering the following questions:
* Can the results observed in controlled clinical trials regarding efficacy and safety be reproduced in the routine clinical setting?
* Are the side-effects of nab-paclitaxel therapy observed in this study comparable to the previously described safety-profile in terms of frequency and intensity?
* What are the main reasons for modification or termination of the nab-paclitaxel therapy?
* How does nab-paclitaxel therapy influence the patients' quality of life?
* What are the criteria for selecting na...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female Patients with metastatic breast cancer, who are at least 18 years old (no upper age limit)
- Exclusion Criteria:
- • Contraindication according to the summary of product characteristics of Abraxane®
- • No signed patient informed consent form available
- • pregnant or breastfeeding patients.
Trial Officials
Christoph Salat, Prof.
Principal Investigator
Haemato-Onkologische Schwerpunktpraxis Franz-Schrank-Strasse 2 80638 Munich, Germany
About Iomedico Ag
iomedico ag is a pioneering clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on developing cutting-edge solutions in the field of healthcare, iomedico ag specializes in conducting clinical studies that prioritize patient safety and data integrity. The company leverages its expertise in clinical trial management, regulatory affairs, and data analysis to support biopharmaceutical companies in bringing novel therapies to market efficiently and effectively. Committed to excellence, iomedico ag collaborates with a network of healthcare professionals and institutions to foster scientific advancements and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Freiburg, Baden Wuerttemberg, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
